164 hasil
Menampilkan 1–20 · 1,37 detik · RSS
Immuno-Oncology and Technology
Scopus
ISSN 2590-0188 · Elsevier · 164 artikel di indeks
-
Artikel Jurnal
The effect of neoadjuvant radiotherapy on immune cell infiltrates in myxofibrosarcoma
Background: Myxofibrosarcoma (MFS) is a subtype of soft-tissue sarcoma for which local treatment includes neoadjuvant radiotherapy (nRT) followed by surgery. The impact of nRT on the MFS tumor immune microenvironment remains unexplored. Materials and methods: Paired pre-nRT biopsy and post-nRT…
-
Artikel Jurnal
Why CD4+ T cells matter in adoptive cell therapy for solid cancers
Cytotoxic CD8+ T cells have been the focus of research efforts to improve the efficacy of anticancer adoptive cell therapies. However, emerging evidence is highlighting the critical role of CD4+ T cells in these treatments, including chimeric antigen receptor-T cells. Although the presence of CD4+…
-
Artikel Jurnal
Corticosteroid exposure, tapering, and survival in immune-related colitis: a 10-year real-world melanoma cohort
Background: Immune-related diarrhoea and colitis (irC) is a common toxicity of immune checkpoint inhibitors (CPIs) in melanoma and frequently requires prolonged corticosteroid (CS) therapy. The impact of CS exposure on CPI efficacy remains uncertain, and evidence guiding tapering strategies and…
-
Artikel Jurnal
Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer
Renal cell carcinoma (RCC) remains one of the most immunologically responsive solid tumors, yet durable benefit from immune checkpoint inhibitors (ICIs) is achieved in only a subset of patients. Although ICIs are conventionally thought to primarily act by reinvigoration and expanding preexisting…
-
Artikel Jurnal
Association between brown adipose tissue activity and clinical outcomes in melanoma: a retrospective PET/CT analysis
Background: Brown adipose tissue (BAT) activity has been suggested to play a role in cancer progression. Previous studies have shown that BAT activity is higher in patients with cancer, and that BAT volume is a predictor of tumour recurrence and mortality in patients with cancer, but the data on…
-
Artikel Jurnal
Germline
Background: Germline BRCA1 (gBRCA1) pathogenic variants (PVs) are the most common cause of inherited breast cancer. Preclinical studies have shown that homozygous loss of BRCA1 in T cells impairs T cell-mediated antitumour immunity. However, the consequences of heterozygous gBRCA1 on human T cell…
-
Artikel Jurnal
Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases
Background: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune disorders marked by the presence of pathogenic autoantibodies predominantly produced by B cells. Both conditions are chronic, incurable, and require lifelong treatment. Chimeric antigen receptor T-cell…
-
Artikel Jurnal
Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer
Background: LOAd703 is a tumor microenvironment (TME) gene-engineering adenovirus encoding the immunostimulatory transgenes trimerized membrane-bound CD40 ligand (CD40L) and 4-1BB ligand (4-1BBL). Upon administration in the TME, the transgenes are expressed in various cell types to engage both the…
-
Artikel Jurnal
Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
Background: Acute myeloid leukemia (AML) is a high-risk malignancy, particularly in patients with primary induction failure or relapsed/refractory disease. CD117 (c-Kit), expressed on both leukemic blasts and normal hematopoietic stem and progenitor cells (HSPCs), represents a potential therapeutic…
-
Artikel Jurnal
Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy
Chimeric antigen receptor (CAR) cellular therapy, particularly CAR-T cells, has revolutionized the treatment of hematologic malignancies. However, these therapies show limited efficacy against solid tumors, in part due to the inefficient trafficking of effector cells to the tumor. This review…
-
Artikel Jurnal
Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma
Background: Tumor-infiltrating lymphocyte (TIL) therapy is effective in metastatic melanoma (MM), but the need for resectable tumor tissue limits its accessibility. Antigen-presenting scaffolds (Ag-scaffolds) constitute a technology developed for the specific expansion of tumor-associated antigen…
-
Artikel Jurnal
Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis
Background: Melanoma patients with pre-existing autoimmune diseases (AIDs) have been excluded from clinical trials of immune checkpoint inhibitors (ICIs), due to a risk of flare and immune-related adverse effects (irAEs). Materials and methods: A comprehensive literature search of Medline, Embase…
-
Artikel Jurnal
Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
Background: The efficacy of immune checkpoint blockade therapy requires pre-existing antitumor immunity. Defective antigen presentation during the priming phase can reduce the generation of tumor-specific T cells, which are necessary during the effector phase and subsequent tumor elimination. We…
-
Artikel Jurnal
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care
Background: The combination of botensilimab + balstilimab demonstrated promising clinical activity in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer (mCRC) in a recently published phase I study (NCT03860272). Patients and methods: Our objective was to derive…
-
Artikel Jurnal
Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies
Background: Cutaneous squamous-cell carcinoma (cSCC) is cured with surgery with or without radiotherapy in most cases, but patients with high-risk features remain prone to recurrence. Until recently, no systemic adjuvant therapy was available. Recently, two phase III trials assessed post-operative…
-
Artikel Jurnal
Subtype-specific genetic drivers of immune evasion in breast cancer
Background: Immune evasion is a hallmark of cancer and a driver of therapeutic resistance. Although immunotherapy is effective in highly immunogenic cancers, its efficacy in breast cancer (BC) remains limited. We aimed to determine the prognostic relevance of immune-related gene signatures across…
-
Artikel Jurnal
Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives
Given their central role in immune regulation, cytokines have long been considered attractive therapeutic agents, particularly in cancer immunotherapy. Despite a strong preclinical and clinical rationale, only a limited number of cytokines have been approved for cancer immunotherapy to date, and…
-
Artikel Jurnal
Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages
Background: Breast cancer is a systemic disease, yet the impact of tumor molecular subtype and disease stage on the systemic immune landscape remains poorly understood. In this study, we comprehensively analyzed the systemic immune landscape in a large cohort of breast cancer patients, encompassing…